--- title: "Oncotelic Therapeutics (OTLC) news: convertible notes" url: "https://aibio.space/companies/oncotelic-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "OTLC convertible notes news: Oncotelic Therapeutics issues $560,000 secured convertible note to Mast Hill Fund. Oncotelic Therapeutics, Inc." --- OTLC Oncotelic Therapeutics, Inc. OTC · United States # Oncotelic Therapeutics (OTLC) news OTLC convertible notes news Company Updates · 2026-04-16 ## [Oncotelic reports $249.0 million 2025 profit that is a non-cash joint venture gain](https://aibio.space/news/oncotelic-reports-249-0-million-2025-profit-non-cash-joint-venture/) The result reflects a non-cash increase of approximately $365.4 million in the fair value of the company's GMP Biotechnology investment, partly offset by a tax provision. ## Latest Oncotelic Therapeutics news 1. 2025-08-06 Debt Financing [Oncotelic Therapeutics issues $560,000 secured convertible note to Mast Hill Fund](https://aibio.space/news/oncotelic-therapeutics-issues-560-000-secured-convertible-note-mast/) Oncotelic's $560,000 note converts at a fixed $0.07 per share and carries 10% interest, and a separate equity purchase agreement with the same lender could add up to $25 million of stock sales. 2. 2025-03-31 Distress [Oncotelic Therapeutics delays 2024 annual report, expects to file within extension](https://aibio.space/news/oncotelic-therapeutics-delays-2024-annual-report-expects-file-within/) The company said it was unable to compile the financial information needed for a complete filing. It does not expect a significant change in results from the prior year. ## Oncotelic Therapeutics at a glance - **Ticker**: OTLC - **Listing**: OTC - **Country**: United States - **Cash, Sep 30, 2025**: $409,000 ### Related companies - [BioAtla](https://aibio.space/companies/bioatla/) OTC: BCAB - [Bio-Path Holdings](https://aibio.space/companies/bio-path/) OTC: BPTH - [Tvardi Therapeutics](https://aibio.space/companies/tvardi-therapeutics/) NASDAQ: TVRD - [Monte Rosa Therapeutics](https://aibio.space/companies/monte-rosa-therapeutics/) NASDAQ: GLUE - [Natera](https://aibio.space/companies/natera/) NASDAQ: NTRA - [Caribou Biosciences](https://aibio.space/companies/caribou-biosciences/) NASDAQ: CRBU - [Calithera Biosciences](https://aibio.space/companies/calithera-biosciences/) OTC: CALA - [PepGen](https://aibio.space/companies/pepgen/) NASDAQ: PEPG ### Also on OTC - [Trevena](https://aibio.space/companies/trevena/) TRVN - [Procaps Group](https://aibio.space/companies/procaps-s-a/) PROCF - [Vicapsys Life Sciences](https://aibio.space/companies/vicapsys-life-sciences/) VICP - [First Choice Healthcare Solutions](https://aibio.space/companies/first-choice-healthcare-solutions/) FCHS - [NEWGEN BIOPHARMA CORP](https://aibio.space/companies/newgen-biopharma/) NEWG - [Nuo Therapeutics](https://aibio.space/companies/nuo-therapeutics/) AURX ## What Oncotelic Therapeutics does Oncotelic Therapeutics, Inc. describes itself as a clinical-stage biopharmaceutical company developing drugs for orphan oncology indications, including antisense and small molecule injectable drugs for cancer. Its OT-101, an antisense against TGF-beta2, is being advanced through a joint venture, GMP Biotechnology Limited, formed with Dragon Overseas Capital, Limited in March 2022. The joint venture also holds five additional nanoparticle compounds. The company holds an exclusive license to AL-101, an intranasal apomorphine asset for Parkinson's disease, erectile dysfunction and female sexual dysfunction. It is also evaluating CA4P, a vascular disrupting agent, in combination with a checkpoint inhibitor for advanced metastatic melanoma, and OXi4503 for acute myeloid leukemia and myelodysplastic syndromes. Further development of Artemisinin has been put on hold. Its subsidiaries include PointR Data, Inc., which works on artificial intelligence technologies for clinical trials, and Pet2DAO, Inc., which the company plans to use to address the animal health industry. | Product or program | What it is | Stage | |---|---|---| | OT-101 | Antisense against TGF-beta2 for cancers and viruses, advanced through a joint venture | Phase 2 completed in South America for COVID-19 pneumonia | | AL-101 | Intranasal apomorphine for Parkinson's disease, erectile dysfunction and female sexual dysfunction | | | CA4P | Vascular disrupting agent with a checkpoint inhibitor for melanoma | Under evaluation; Rare Pediatric Designation granted | Summarised from the company's [10-K filed Apr 15, 2026](https://www.sec.gov/Archives/edgar/data/908259/000149315226016838/form10-k.htm). ## Oncotelic Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$4,357](https://www.sec.gov/Archives/edgar/data/908259/000149315226016838/) | | | Net income (loss) | [$249.3 million](https://www.sec.gov/Archives/edgar/data/908259/000149315226016838/) | [-$4.5 million](https://www.sec.gov/Archives/edgar/data/908259/000149315226016838/) | | Cash from operations | [-$1.4 million](https://www.sec.gov/Archives/edgar/data/908259/000149315226016838/) | [-$740,277](https://www.sec.gov/Archives/edgar/data/908259/000149315226016838/) | | Cash and equivalents | | [$86,128](https://www.sec.gov/Archives/edgar/data/908259/000149315225023834/) | Latest balance sheet, Sep 30, 2025 (10-Q): cash and equivalents $409,000. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Oncotelic Therapeutics Has Oncotelic Therapeutics sold convertible notes? Our latest story on this, dated Aug 6, 2025: "Oncotelic Therapeutics issues $560,000 secured convertible note to Mast Hill Fund". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/oncotelic-therapeutics-issues-560-000-secured-convertible-note-mast/). What is the ticker symbol of Oncotelic Therapeutics? Oncotelic Therapeutics, Inc. trades under the ticker OTLC on OTC. Where is Oncotelic Therapeutics listed? Oncotelic Therapeutics, Inc. is listed on OTC. What is the SEC CIK of Oncotelic Therapeutics? The SEC Central Index Key (CIK) for Oncotelic Therapeutics, Inc. is 908259. Its filings are on SEC EDGAR. How many shares does Oncotelic Therapeutics have outstanding? 457,512,796 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Oncotelic Therapeutics listed under? Our directory records Oncotelic Therapeutics, Inc. under United States. What does Oncotelic Therapeutics do? Our directory classifies Oncotelic Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Oncotelic Therapeutics? The ISIN recorded for Oncotelic Therapeutics, Inc. is US6283411097. Does aibio.space cover Oncotelic Therapeutics? aibio.space lists Oncotelic Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Oncotelic Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Oncotelic Therapeutics develop? Oncotelic Therapeutics, Inc. describes itself as a clinical-stage biopharmaceutical company developing drugs for orphan oncology indications, including antisense and small molecule injectable drugs for cancer. Its OT-101, an antisense against TGF-beta2, is being advanced through a joint venture, GMP Biotechnology Limited, formed with Dragon Overseas Capital, Limited in March 2022. What is OT-101 from Oncotelic Therapeutics? OT-101: Antisense against TGF-beta2 for cancers and viruses, advanced through a joint venture Stage: Phase 2 completed in South America for COVID-19 pneumonia. What is AL-101 from Oncotelic Therapeutics? AL-101: Intranasal apomorphine for Parkinson's disease, erectile dysfunction and female sexual dysfunction Stage: Not stated in text. Is Oncotelic Therapeutics profitable? Oncotelic Therapeutics, Inc. reported net income of $249.3 million for the fiscal year ended Dec 31, 2025, and used $1.4 million of cash in operations, per its annual report to the SEC. How much does Oncotelic Therapeutics spend on research and development? $4,357 in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Oncotelic Therapeutics Members talk about Oncotelic Therapeutics (OTLC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Oncotelic Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-07-14 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/908259/000149315226033171/form8-k.htm) 2. 2026-05-05 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/form8-k.htm) 3. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/908259/000149315226014324/formnt10-k.htm) 4. 2025-11-21 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/908259/000149315225024676/forms-1.htm) 5. 2025-11-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/908259/000149315225023634/formnt10-q.htm) 6. 2025-08-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/908259/000164117225022361/form8-k.htm) 7. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/908259/000164117225001610/formnt10-k.htm) 8. 2024-11-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/908259/000149315224046049/formnt10-q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:OTLC on TradingView](https://www.tradingview.com/symbols/OTC-OTLC/). ## SEC filings and registration - **SEC name**: Oncotelic Therapeutics, Inc. - **CIK**: 908259 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: OTLC (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 29397 AGOURA RD., AGUORA HILLS, CA, 91301 - **Phone**: 650-635-7000 - **Shares outstanding**: 457,512,796 as of 2026-08-13 (10-Q filed 2026-08-13) - **Former names**: MATEON THERAPEUTICS INC; OXIGENE INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/908259/000149315226046751/form8-k.htm) filed 2026-10-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/908259/000149315226037857/form10-q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/908259/000149315226035999/form8-k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/908259/000149315226033172/form8-k.htm) filed 2026-07-14 - [8-K](https://www.sec.gov/Archives/edgar/data/908259/000149315226033171/form8-k.htm) filed 2026-07-14 - [8-K](https://www.sec.gov/Archives/edgar/data/908259/000149315226031124/form8-k.htm) filed 2026-06-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/908259/000149315226023181/form10-q.htm) filed 2026-05-14 - [8-K](https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/form8-k.htm) filed 2026-05-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000908259), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Oncotelic Therapeutics, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker OTLC, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Oncotelic Therapeutics, Inc. - **Ticker**: OTLC - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US6283411097 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-OTLC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/oncotelic-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Oncotelic Therapeutics (OTLC) news: convertible notes", 2026-10-31, https://aibio.space/companies/oncotelic-therapeutics/